Osocimab, formerly known as BAY 1213790, represents a unique monoclonal immunoglobulin currently in clinical development for the treatment of several hematologic tumors. This compound primarily targets CD38, a membrane https://lexiezxvi414081.blog-gold.com/58869939/osocimab-a-deep-analysis-into-bay-1213790-and-its-outlook